Table 1.
Comparison of clinical characteristics of MPP between the immunosuppressant and non-immunosuppressant groups.
| Non-immunosuppressant group (n = 789/3370) |
Immunosuppressant group (n = 19/201) |
P value | |
|---|---|---|---|
| MP incidence, % | 23.41 | 9.45 | 0.000 |
| Age, years | 3.57 ± 2.797 | 3.79 ± 2.76 | 0.222 |
| Sex (male/female) | 428/361 | 9/10 | 0.553 |
| Complications | 159 (20.15%) | 3 (15.78%) | 0.001 |
| Severe cases | 220 (27.8%) | 0 (0%) | 0.000 |
| WBC × 109/L | 9.80 ± 4.51 | 6.01 ± 7.26 | 0.000 |
| Neutrophils × 109/L | 5.46 ± 3.49 | 2.43 ± 2.46 | 0.001 |
| Lymphocytes × 109/L | 3.36 ± 2.55 | 2.81 ± 5.56 | 0.669 |
| CRP, mg/L | 16.32 ± 20.78 | 43.19 ± 44.34 | 0.043 |
| LDH, IU/L | 383.80 ± 216.16 | 297.18 ± 109.69 | 0.099 |
MPP, Mycoplasma pneumoniae pneumonia; MP, Mycoplasma pneumoniae; WBC, white blood cells; CRP, C-reactive protein; LDH, L-lactate dehydrogenase. Data are presented as mean ± standard deviation or number (percentage).